Solgate is a leading drug discovery company specializing in membrane transporters known as solute carriers (SLCs). To further explore the potential of SLC targets, Solgate has partnered with Curie.Bio, a Boston-based venture firm specializing in therapeutic companies. Together, they have selected two molecular targets from the broader repertoire, while Solgate continues to advance its technology platform and independent pipeline. This collaboration, established through the US-based Cellgate Therapeutics Inc., brings together Solgate’s skilled biology and chemistry teams in Austria with Curie.Bio’s drug discovery and development expertise and network in the US. 

For more information, contact: office@solgate.com

Solgate GmbH pursues the development of drugs modulating the activity of SLC proteins, focusing on the important roles of SLCs in neurological, autoimmune, and metabolic disorders. Through a proprietary discovery platform that combines several technologies, Solgate designs and rapidly advances novel chemical matter against selected SLCs. Solgate GmbH was founded by Ariel Bensimon, Georg Winter, Stefan Kubicek, Giulio Superti-Furga, and Gaia Novarino, together with CeMM and IST Austria.